{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T07:17:38Z","timestamp":1778224658168,"version":"3.51.4"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"British Association of Dermatologists Biologic Register Ltd"},{"DOI":"10.13039\/501100000545","name":"British Association of Dermatologists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000545","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Biologics and Immunomodulators Register"},{"DOI":"10.13039\/100014653","name":"NIHR Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Since the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) was established in 2007, numerous biologic therapies have been introduced for the better management of psoriasis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To describe baseline demographics, disease characteristics and real-world biologic utilization in patients entering BADBIR over time.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with moderate-to-severe psoriasis registered in BADBIR between 2007 and 2024 were included. Percentages were used to describe categorical variables and the median with interquartile range (IQR) for continuous variables. The year of enrolment was divided into Early (2007\u20132014) and Late (2015\u20132024) periods.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>As of April 2024, there were 21 407 registrations in BADBIR. Compared with the Early period, more minority ethnic groups [1374\/11 383 (12.1%) vs. 868\/10 024 (8.7%)] were enrolled in the Late period. Shorter disease duration [median years, 18 (IQR 10\u201328) vs. 20 (11\u201329)], lower severity measured using Psoriasis Area and Severity Index [median 11 (IQR 6\u201316) vs. 14 (IQR 10\u201319)] and fewer patients with comorbidities [6298\/11 383 (55.3%) vs. 5905\/10 024 (58.9%)] were reported in the Late vs. the Early period. There were 6236 (29.1%) patients in the conventional cohort and 15 171 (70.9%) in the biologic cohort from 2007 to 2024 (total N = 21 407). Out of 15 171 individuals in the biologic cohort, 8299 (54.7%), 3227 (21.3%) and 1170 (7.7%) switched to second, third and fourth lines of therapy, respectively. In 15 171 individuals (2007\u20132024), adalimumab was the most frequently prescribed first-line therapy, followed by ustekinumab and etanercept [6576 (43.4%), 3349 (22.1%) and 1750 (11.5%), respectively]. Despite the significant drop in utilization over time, adalimumab remained the most frequent first-line biologic in the Late period 3092\/8716 (35.5%), followed by ustekinumab 2087\/8716 (23.9%) and secukinumab 1445\/8716 (16.6%). However, utilization of biologics in the subsequent lines of therapies has changed over time in newer biologics, with mainly guselkumab and risankizumab becoming the most frequent in recent years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients registered in the Late period have less severe psoriasis, shorter disease duration and fewer comorbidities than those enrolled in the Early period. The most frequent biologics at enrolment were adalimumab and ustekinumab; however, this has changed with the introduction of new and more effective biologics. BADBIR is a rich data source providing information on the management of psoriasis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llaf224","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T10:48:37Z","timestamp":1747910917000},"page":"1995-2006","source":"Crossref","is-referenced-by-count":3,"title":["Evaluating changes in baseline characteristics and drug-utilization pattern in patients with moderate-to-severe psoriasis: findings from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) cohort"],"prefix":"10.1093","volume":"50","author":[{"given":"Oras A","family":"Alabas","sequence":"first","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, The University of Manchester , Manchester ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Evans","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, The University of Manchester , Manchester ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Mcelhone","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, The University of Manchester , Manchester ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1831-074X","authenticated-orcid":false,"given":"Zenas Z N","family":"Yiu","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, The University of Manchester , Manchester ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick J","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Royal Victoria Infirmary and NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals NHS Foundation Trust, Institute of Translational and Clinical Medicine, Medical School, Newcastle University , Newcastle upon Tyne ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4628-0699","authenticated-orcid":false,"given":"Philip","family":"Laws","sequence":"additional","affiliation":[{"name":"Leeds Dermatology Centre, Leeds Teaching Hospitals NHS Trust , Leeds ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Bewley","sequence":"additional","affiliation":[{"name":"Barts Health NHS Trust & Queen Mary University , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine H","family":"Smith","sequence":"additional","affiliation":[{"name":"St John's Institute of Dermatology, Guy's and St Thomas\u2019 NHS Foundation Trust and King's College London , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Lunt","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, The University of Manchester , Manchester ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher E M","family":"Grif\ufb01ths","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, The University of Manchester , Manchester ,","place":["UK"]},{"name":"St John's Institute of Dermatology, Guy's and St Thomas\u2019 NHS Foundation Trust and King's College London , London ,","place":["UK"]},{"name":"Department of Dermatology, King\u2019s College Hospital, King\u2019s College London , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-6481","authenticated-orcid":false,"given":"Richard B","family":"Warren","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, The University of Manchester , Manchester ,","place":["UK"]},{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the BADBIR Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Barker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Bewley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shehnaz","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Kleyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Laws","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Hampton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oras","family":"Alabas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"McElhone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zenas","family":"Yiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teena","family":"Mackenzie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tess","family":"McPherson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Ormerod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shernaz","family":"Walton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa","family":"Shipman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Weller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girish","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Zietemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"2025092509025483700_llaf224-B1","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"2025092509025483700_llaf224-B2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025092509025483700_llaf224-B3","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/jid.2013.508","article-title":"The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis","volume":"134","author":"Dowlatshahi","year":"2014","journal-title":"J Invest Dermatol"},{"key":"2025092509025483700_llaf224-B4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025092509025483700_llaf224-B5","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"2025092509025483700_llaf224-B6","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjd.18245","article-title":"Management of psoriasis as a systemic disease: what is the evidence?","volume":"182","author":"Korman","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025092509025483700_llaf224-B7","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1742-1241.2009.02056.x","article-title":"Observational studies: a review of study designs, challenges and strategies to reduce confounding","volume":"63","author":"Lu","year":"2009","journal-title":"Int J Clin Pract"},{"key":"2025092509025483700_llaf224-B8","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2133.2012.10835.x","article-title":"The British Association of Dermatologists\u2019 Biologic Interventions Register (BADBIR): design, methodology and objectives","volume":"166","author":"Burden","year":"2012","journal-title":"Br J Dermatol"},{"key":"2025092509025483700_llaf224-B9","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/bjd.13908","article-title":"Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register","volume":"173","author":"Iskandar","year":"2015","journal-title":"Br J Dermatol"},{"key":"2025092509025483700_llaf224-B10"},{"key":"2025092509025483700_llaf224-B11","author":"Naqvi"},{"key":"2025092509025483700_llaf224-B12","first-page":"48","article-title":"German psoriasis registry PsoBest: objectives, methodology and baseline data","volume":"12","author":"Augustin","year":"2014","journal-title":"J Dtsch Dermatol Ges"},{"key":"2025092509025483700_llaf224-B13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40259-016-0209-y","article-title":"Regional differences in the prescription of biologics for psoriasis in Sweden: a register-based study of 4168 patients","volume":"31","author":"Calara","year":"2017","journal-title":"BioDrugs"},{"key":"2025092509025483700_llaf224-B14","doi-asserted-by":"crossref","first-page":"151979","DOI":"10.1016\/j.semarthrit.2022.151979","article-title":"Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis \u2013 a nationwide cohort study from the DANBIO and DERMBIO registries","volume":"53","author":"Egeberg","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2025092509025483700_llaf224-B15","doi-asserted-by":"crossref","first-page":"2350227","DOI":"10.1080\/09546634.2024.2350227","article-title":"Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)","volume":"35","author":"Pinter","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"2025092509025483700_llaf224-B16","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ad.2022.12.001","article-title":"Erythrodermic psoriasis has become less frequent: results from the BIOBADADERM registry","volume":"114","author":"Rivera-Diaz","year":"2023","journal-title":"Actas Dermosifiliogr"},{"key":"2025092509025483700_llaf224-B17","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jdv.16566","article-title":"Epidemiologic study in a real-world analysis of patients with treatment for psoriasis in the French national health insurance database","volume":"35","author":"Grodner","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025092509025483700_llaf224-B18","first-page":"249","article-title":"Pso-Reg: a web registry for psoriasis in real life","volume":"158","author":"Trovato","year":"2023","journal-title":"Ital J Dermatol Venerol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf224\/63294851\/llaf224.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/10\/1995\/63294851\/llaf224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/10\/1995\/63294851\/llaf224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:03:03Z","timestamp":1758805383000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/10\/1995\/8140680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":18,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5,22]]},"published-print":{"date-parts":[[2025,9,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf224","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,5,22]]}}}